Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Related news

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

FHTXFoghorn Therapeutics2026-06-25 13:46 EST

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

View all latest news

Foghorn Therapeutics

Foghorn Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

FHTXFoghorn Therapeutics2026-06-26 08:47 EST

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

FHTXFoghorn Therapeutics2026-06-26 08:47 EST

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

FHTXFoghorn Therapeutics2026-06-26 08:47 EST

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-06-26 08:47 EST

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-06-26 08:47 EST

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States